C6orf183 Inhibitors
The chemical class termed C6orf183 Inhibitors encompasses a diverse set of compounds with distinct mechanisms of action targeting various cellular pathways. Forskolin, through adenylate cyclase activation, increases cAMP levels, indirectly influencing C6orf183-related pathways. GW0742, a PPARδ agonist, and rosiglitazone, a PPARγ agonist, modulate gene expression and cellular processes associated with C6orf183. Inhibition of GSK-3 by 6-Bromoindirubin-3'-oxime impacts Wnt/β-catenin signaling, potentially affecting C6orf183. NSC23766, by inhibiting Rac1, influences multiple signaling pathways, while A769662, as an AMPK activator, modulates cellular energy balance, indirectly impacting C6orf183-related processes. Trichostatin A, an HDAC inhibitor, alters chromatin structure, potentially affecting gene expression linked to C6orf183.
Ionomycin increases intracellular calcium levels, activating signaling cascades that may indirectly influence C6orf183. LY294002 inhibits PI3K, disrupting the PI3K/Akt pathway, potentially impacting downstream events. SB-431542 inhibits the TGF-β type I receptor, disrupting TGF-β signaling, and PD98059 inhibits MEK1, disrupting the MAPK/ERK pathway, both potentially influencing cellular processes related to C6orf183. SB-216763, a GSK-3 inhibitor, modulates Wnt/β-catenin signaling, providing a diverse array of inhibitors that can collectively influence cellular processes associated with C6orf183.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 0742 | 317318-84-6 | sc-203991 sc-203991A | 10 mg 50 mg | $194.00 $831.00 | 11 | |
GW0742 is a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist. Activation of PPARδ can affect gene expression and potentially impact pathways associated with C6orf183. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone is a PPARγ agonist. Activation of PPARγ influences gene expression and can modulate cellular processes that may indirectly affect C6orf183. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A769662 is an AMP-activated protein kinase (AMPK) activator. Activated AMPK can modulate cellular energy balance, indirectly influencing pathways associated with C6orf183. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase (HDAC) inhibitor. Inhibition of HDACs can alter chromatin structure and gene expression, potentially impacting cellular processes linked to C6orf183. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin is a calcium ionophore, increasing intracellular calcium levels. Elevated calcium levels can activate various signaling cascades that may indirectly influence C6orf183. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. Inhibition of PI3K disrupts the PI3K/Akt pathway, potentially impacting downstream signaling events related to C6orf183. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 inhibits the TGF-β type I receptor, disrupting TGF-β signaling. Inhibition of this pathway may indirectly influence cellular processes associated with C6orf183. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK1, an upstream regulator of ERK1/2. Inhibition of MEK1 disrupts the MAPK/ERK pathway, potentially influencing cellular events related to C6orf183. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB-216763 is a glycogen synthase kinase 3 (GSK-3) inhibitor. Inhibition of GSK-3 can impact Wnt/β-catenin signaling, potentially influencing cellular processes associated with C6orf183. | ||||||